About Us
Our Company
Management & Board
Aceragen
Tilsotolimod
Toll-Like Receptor Activation
Publications & Presentations
Investor Relations
×
Design of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400, a Toll-like receptor antagonist, in patients with dermatomyositis
